Genelux presents update on Olvi-Vec phase 3 ovarian cancer trial
GNLX•
GNLX•Genelux expects topline results from its pivotal Phase 3 Olvi-Vec trial for platinum-resistant or refractory ovarian cancer in the second half of 2026. Pro forma cash is approximately $16 million, providing runway into the first quarter of 2027.
Genelux expects topline results from its pivotal Phase 3 Olvi-Vec trial in platinum-resistant or refractory ovarian cancer in the second half of 2026. FDA alignment could support traditional approval without a confirmatory trial if progression-free survival improves meaningfully without an overall survival decline.
Pro forma cash totals approximately $16 million, providing runway into the first quarter of 2027. Average quarterly operating cash burn is approximately $7 million, and capital expenditures could reach approximately $6 million. Genelux expects additional dose-finding updates from systemic Olvi-Vec trials in recurrent small cell and non-small cell lung cancer in 2026.